This article is authored by Ranjit Barshikar, CEO, QbD International, CGMP Consulting, United Nations Adviser.

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus. Lantus cost $292 for a 30-day supply. Drugmaker Viatris launched two versions ...

For India to compete, it must transition from being the “pharmacy of the world” to the “innovation engine of the world.” ...

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus. Lantus cost $292 for a 30-day supply. Drugmaker Viatris launched two versions ...

THURSDAY, Jan. 23, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has warned the pharmaceutical company Sanofi about significant deviations from Current Good Manufacturing Practice for ...

23, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has warned the pharmaceutical company Sanofi about significant deviations from Current Good Manufacturing Practice for active ...

The FDA issued a warning letter to Sanofi regarding significant manufacturing violations at its Genzyme Corporation Facility in Framingham, Mass. The letter, dated Dec. 16, 2024, and amended Jan.

We would like to use cookies to collect information about how you use ons.gov.uk. We use this information to make the website work as well as possible and improve our services.

as well as Good Manufacturing Practices (GMP), which emphasizes the need to comply with strict quality and safety standards throughout all manufacturing processes. The cost of non-compliance ...

The Federal Trade Commission has released its second report digging into how the business practices of pharmacy benefit managers ... They could also be good for PBMs: Commissioner Ferguson recused ...

WASHINGTON, Jan 14 (Reuters) - The nation's three largest pharmacy benefit managers have ... over the study period from spread pricing - the practice of billing plan sponsors more than they ...